Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (182 reviews)

For research use only.

Catalog No.S1001

182 publications

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 182 publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )
Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )
Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )
Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )
Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )
J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )
Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M1;D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXQZnBKSzVyPUCuNFA3PjlizszN	MkfyV2FPT0WU
MV-4-11	NXjyTXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PwU2lEPTB;MD6wNVU5PiEQvF2=	M3LCcHNCVkeHUh?=
NKM-1	NUfWcWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\ITWM2OD1yLkCxOlk6KM7:TR?=	MWrTRW5ITVJ?
ML-2	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEG5PFMh\|ryP	MmjBV2FPT0WU
BV-173	NIP6XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHvPFgzUUN3ME2wMlAzOzF2IN88US=>	MU\TRW5ITVJ?
RS4-11	M3H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTCTWM2OD1yLkCyOVg4KM7:TR?=	MmXzV2FPT0WU
HL-60	NEO1bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMEK5NFgh\|ryP	NEXnWJRUSU6JRWK=
KY821	M2rmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfFTWM2OD1yLkCyPVc2KM7:TR?=	MUPTRW5ITVJ?
ECC10	NVP6T4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP3cFJKSzVyPUCuNFM4QTJizszN	NWriTXlRW0GQR1XS
NCI-H720	M2nMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TVWWlEPTB;MD6wOFAyOSEQvF2=	NI\JemhUSU6JRWK=
QIMR-WIL	NETWPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HScmlEPTB;MD6wOFI5PyEQvF2=	MoXXV2FPT0WU
KG-1	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn64TWM2OD1yLkC0OFg3KM7:TR?=	M37ISnNCVkeHUh?=
TGW	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPxTWM2OD1yLkC0OlM{KM7:TR?=	MlTMV2FPT0WU
ATN-1	NHy3OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMES3N\|Mh\|ryP	Mo[wV2FPT0WU
RH-18	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzPTWM2OD1yLkC2NFQ5KM7:TR?=	MojJV2FPT0WU
EW-18	NHnvW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfHTWM2OD1yLkC2PFQyKM7:TR?=	M4\0XnNCVkeHUh?=
NB17	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG1R21KSzVyPUCuNFcyOjRizszN	M3W0fHNCVkeHUh?=
SK-NEP-1	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEeyNVMh\|ryP	M4DEcXNCVkeHUh?=
P12-ICHIKAWA	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPSc5g1UUN3ME2wMlA4Pzd6IN88US=>	M2q0Z3NCVkeHUh?=
KARPAS-45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEe4NVUh\|ryP	MUHTRW5ITVJ?
EW-3	M4LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4q5c2lEPTB;MD6wPFA2OyEQvF2=	MUPTRW5ITVJ?
NB13	NXPrR4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPHTWM2OD1yLkC4NlA{KM7:TR?=	MWjTRW5ITVJ?
NCI-H209	M4T3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTtT3ZJUUN3ME2wMlA5PzB2IN88US=>	MljIV2FPT0WU
NCI-H1092	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjzZVJ2UUN3ME2wMlExOjd3IN88US=>	NH;v[mZUSU6JRWK=
NH-12	NILmV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M374[GlEPTB;MD6xNFc1PCEQvF2=	NFzlSFNUSU6JRWK=
697	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1P3PWlEPTB;MD6xNFg{QSEQvF2=	MVXTRW5ITVJ?
KE-37	M1fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjNNJlKSzVyPUCuNVE{PyEQvF2=	NXixd2Z{W0GQR1XS
MOLT-4	NYmyU2xET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXGyend2UUN3ME2wMlE2OTZ7IN88US=>	MU\TRW5ITVJ?
CHP-134	NV24eHBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjYWnVJUUN3ME2wMlE3OzB4IN88US=>	MoTOV2FPT0WU
D-283MED	NYHOTHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXpTWM2OD1yLkG3Olg3KM7:TR?=	MX7TRW5ITVJ?
LU-135	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvYcndKSzVyPUCuNVg2PTJizszN	MmnaV2FPT0WU
LU-134-A	M{nje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWm2[2dVUUN3ME2wMlE5PjdzIN88US=>	NHzxRm9USU6JRWK=
EM-2	NYiydppNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPtNZFKSzVyPUCuNVk6OThizszN	NUezeWVKW0GQR1XS
LU-139	M2rUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMkC0PVgh\|ryP	MmDvV2FPT0WU
ALL-PO	NGfNNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nOTmlEPTB;MD6yNVk5QCEQvF2=	NFf1NVJUSU6JRWK=
NB12	NHv2[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzGOVI{UUN3ME2wMlI{OTF3IN88US=>	MYrTRW5ITVJ?
KP-N-YN	NV3FPFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXWzcIZ{UUN3ME2wMlI{PTd\|IN88US=>	NHnmNZhUSU6JRWK=
BEN	NUDwU3VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMkO5Olgh\|ryP	MlTVV2FPT0WU
HCC1569	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGGwWo9KSzVyPUCuNlUyODZizszN	M3zpXnNCVkeHUh?=
HuO9	M1vvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HYW2lEPTB;MD6yOlcyPSEQvF2=	NEjGc4dUSU6JRWK=
WM-115	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rVVmlEPTB;MD6yO\|c{QCEQvF2=	MlHEV2FPT0WU
CCRF-CEM	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfYeo5KSzVyPUCuN\|M2OjlizszN	MnqzV2FPT0WU
IST-SL1	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwM{WzOFMh\|ryP	MVLTRW5ITVJ?
BE-13	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESxNVBKSzVyPUCuN\|Y1PTlizszN	MmPrV2FPT0WU
COR-L88	NHzzbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPYTWM2OD1yLkO2OVQh\|ryP	MkLrV2FPT0WU
DOHH-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTrSFBxUUN3ME2wMlQyODJ\|IN88US=>	NVTMNIpDW0GQR1XS
A704	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPVTWM2OD1yLkSyOlch\|ryP	NVixOI03W0GQR1XS
KNS-81-FD	NUXmcYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DnUmlEPTB;MD60OFAyPyEQvF2=	M1LodnNCVkeHUh?=
RPMI-8226	M{[xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33UeGlEPTB;MD60OVY2OiEQvF2=	NVi0d\|E{W0GQR1XS
TGBC24TKB	NW[zVndIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D1[mlEPTB;MD60OVc4QCEQvF2=	MlzYV2FPT0WU
NCI-H1304	M4XRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfxdYVKSzVyPUCuOFYyPTdizszN	M2O4b3NCVkeHUh?=
MOLT-13	NHmwNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3P[JRbUUN3ME2wMlQ3PjF\|IN88US=>	NFvTRVlUSU6JRWK=
EW-22	NWHmcpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF31cYNKSzVyPUCuOFY3PzFizszN	NH\qZ41USU6JRWK=
MS-1	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrXTWM2OD1yLkS2PVM{KM7:TR?=	NWjTfYlrW0GQR1XS
RMG-I	M{PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwNEm0OlQh\|ryP	NHLlb3BUSU6JRWK=
NTERA-S-cl-D1	NWX2OHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXIUW5ZUUN3ME2wMlUxODF7IN88US=>	M1XGRXNCVkeHUh?=
NCI-H1048	M2TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjiTWM2OD1yLkWwPVU{KM7:TR?=	NH\UfJBUSU6JRWK=
SW1417	NGTDRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfFTWM2OD1yLkW1OFM5KM7:TR?=	M4i4VXNCVkeHUh?=
DB	NHjm[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP0emhKSzVyPUCuOVcxQCEQvF2=	MmnZV2FPT0WU
MEG-01	NHzJZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TDOmlEPTB;MD61PFMzKM7:TR?=	NFfJO\|FUSU6JRWK=
EW-13	NV[2R4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[5UmlKSzVyPUCuOVg{PDFizszN	NXTrV2JSW0GQR1XS
LAMA-84	M33JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjCeGV5UUN3ME2wMlU6OjB5IN88US=>	NVf2UnRpW0GQR1XS
J-RT3-T3-5	NXTYVldXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDvVYRKSzVyPUCuOlA5ODhizszN	M3W1bXNCVkeHUh?=
MOLT-16	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;3TWM2OD1yLk[1NlY1KM7:TR?=	MmXIV2FPT0WU
DU-4475	MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\FW2lFUUN3ME2wMlY2PDJ5IN88US=>	NIrIVJlUSU6JRWK=
HAL-01	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwN{K1OFkh\|ryP	NEnoUZZUSU6JRWK=
RD	M4\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\xTWM2OD1yLke1PFk6KM7:TR?=	MUDTRW5ITVJ?
OAW-28	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrkdGlKSzVyPUCuO\|g{PyEQvF2=	NHmzZ\|dUSU6JRWK=
HCC38	NFrUXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXYb5FKSzVyPUCuPFAyQSEQvF2=	NEPFeIxUSU6JRWK=
NMC-G1	M2S4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwOEGxNlEh\|ryP	MW\TRW5ITVJ?
EW-16	NH;0T41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4CxemlEPTB;MD64NVMzQCEQvF2=	MlvwV2FPT0WU
DU-145	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwOEm5NlMh\|ryP	NHnoOHBUSU6JRWK=
HPAF-II	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwOUK2Nlgh\|ryP	MnzpV2FPT0WU
A427	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\Je2pKSzVyPUCuPVMxOjJizszN	NEH0[m9USU6JRWK=
PA-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPVdYczUUN3ME2wMlk2PjR{IN88US=>	M1ewSnNCVkeHUh?=
OAW-42	M4PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO0fJpKSzVyPUCuPVYyPDZizszN	M1i3TnNCVkeHUh?=
L-428	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHIS3JKSzVyPUGuNFEzPSEQvF2=	NWrmU3VKW0GQR1XS
COLO-824	NWnaVG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwMEG3NFgh\|ryP	NVjSTINGW0GQR1XS
P30-OHK	NVrabY56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXZTWM2OD1zLkC0Olg5KM7:TR?=	M2nXcnNCVkeHUh?=
NCI-H2170	M1Ltd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ryNGlEPTB;MT6wOlI{KM7:TR?=	NIjXUVJUSU6JRWK=
HCC2998	M3vtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXsbYdKSzVyPUGuNFcyOzVizszN	M1LJUXNCVkeHUh?=
NB14	NVXkU45qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUP1NYxSUUN3ME2xMlE{PzR6IN88US=>	MXXTRW5ITVJ?
TGBC1TKB	NFK3fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTFwMUSxOVIh\|ryP	NVjaeZQ5W0GQR1XS
KP-N-YS	NIjqeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HtTmlEPTB;MT6xOlI{PiEQvF2=	MVHTRW5ITVJ?
CAL-120	NVfBNI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLrTWM2OD1zLkG2OFI6KM7:TR?=	MkTuV2FPT0WU
SBC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXNPZlWUUN3ME2xMlE6ODV\|IN88US=>	Mn3TV2FPT0WU
C32	M3zG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TtTWlEPTB;MT6xPVA5QCEQvF2=	MVrTRW5ITVJ?
HCC2157	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTFwMUm0PVQh\|ryP	NF72SYZUSU6JRWK=
COLO-792	NEn5Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mof6TWM2OD1zLkKwNFcyKM7:TR?=	NGTXN\|RUSU6JRWK=
ES7	M1fWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwMke5OVEh\|ryP	Mn;OV2FPT0WU
HEL	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXsZZFQUUN3ME2xMlMyODJ7IN88US=>	NGO5fnFUSU6JRWK=
ES4	M362eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[yUGlEPTB;MT6zOFk6QCEQvF2=	MXPTRW5ITVJ?
NCI-SNU-1	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFwM{[1OVUh\|ryP	MnHiV2FPT0WU
MDA-MB-415	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rybWlEPTB;MT6zPFg2KM7:TR?=	M{HwfXNCVkeHUh?=
NCI-H2342	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwNECyOlkh\|ryP	NV60dI5[W0GQR1XS
NB69	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTFwNE[yO\|Eh\|ryP	NHnD[ppUSU6JRWK=
D-247MG	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nTcGlEPTB;MT61NVEzOiEQvF2=	M4\zeHNCVkeHUh?=
SCC-4	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoKyTWM2OD1zLkW5PFg4KM7:TR?=	MoOzV2FPT0WU
HuH-7	NIm3UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moq4TWM2OD1zLk[3Nlk{KM7:TR?=	NF7FU2pUSU6JRWK=
A388	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTFwNki3NlQh\|ryP	NGfTVWpUSU6JRWK=
Calu-3	M4HOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTWO5VKSzVyPUGuO\|A3QTdizszN	MonJV2FPT0WU
NCI-H1648	M3yxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\nUHlKSzVyPUGuO\|E1OThizszN	MWrTRW5ITVJ?
NCI-H2052	M1zZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jzW2lEPTB;MT63NlIxOSEQvF2=	NYP1V3B[W0GQR1XS
Ramos-2G6-4C10	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\OTWM2OD1zLkezOlU3KM7:TR?=	MV;TRW5ITVJ?
DEL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3nVGdKSzVyPUGuO\|Q3QTJizszN	NULUUpp5W0GQR1XS
SNU-423	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37yUWlEPTB;MT63PFE2PyEQvF2=	MUXTRW5ITVJ?
COR-L23	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz1V25KSzVyPUGuO\|k5PzRizszN	NGm2cphUSU6JRWK=
OMC-1	NYnSd4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXZTWM2OD1zLki2NFE3KM7:TR?=	NEm3T4ZUSU6JRWK=
EW-11	NH3CS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknFTWM2OD1zLkm1OlU4KM7:TR?=	MXjTRW5ITVJ?
HSC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPWe446UUN3ME2xMlk3OzZ3IN88US=>	NVrqdWVbW0GQR1XS
MLMA	M1;TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n0cWlEPTB;MT65OlY4PyEQvF2=	MkfwV2FPT0WU
RCM-1	NWe0XI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fyVGlEPTB;Mj6wNFM6QSEQvF2=	M2nSeHNCVkeHUh?=
MFE-280	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJwMEK4OFgh\|ryP	MoT3V2FPT0WU
ES8	NEPMUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTlWnVVUUN3ME2yMlI2PDdzIN88US=>	NU\oclAyW0GQR1XS
TE-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmmxTWM2OD1{LkK5OFc{KM7:TR?=	MUTTRW5ITVJ?
HuO-3N1	NXXs[\|JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1n6dWlEPTB;Mj60PFc5KM7:TR?=	MWPTRW5ITVJ?
MHH-NB-11	NFPMVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJwNUGxOVgh\|ryP	NIXpPFlUSU6JRWK=
TGBC11TKB	M2rWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rFVGlEPTB;Mj61O\|Y5OSEQvF2=	Ml;0V2FPT0WU
HOP-92	NWKyNZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDPbFFUUUN3ME2yMlU5PzR\|IN88US=>	NWTSO2xiW0GQR1XS
IGR-1	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHVbXNDUUN3ME2yMlYzODN3IN88US=>	NYHnU\|JCW0GQR1XS
GOTO	NVjrNplkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7pPGdKSzVyPUKuOlU{PzdizszN	M1TJ[XNCVkeHUh?=
NCI-H1650	M2SxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fsTWlEPTB;Mj63NlIyPSEQvF2=	M360SXNCVkeHUh?=
NCI-H1581	NH[wXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTJwN{m2PFEh\|ryP	NIPISGZUSU6JRWK=
NCI-H2405	NXWwOGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXIcYZKSzVyPUKuPFI4QDJizszN	MnS5V2FPT0WU
U-118-MG	NGjSOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV65OmNCUUN3ME2yMlk3PDlzIN88US=>	MWPTRW5ITVJ?
DoTc2-4510	M4jiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTNwMEG0NVch\|ryP	NV3se5R[W0GQR1XS
NCI-H596	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTNwMES5PVch\|ryP	MWTTRW5ITVJ?
MPP-89	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnGwTWM2OD1\|LkC1OlY3KM7:TR?=	NF\mVXRUSU6JRWK=
GCIY	Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnDTXJVUUN3ME2zMlIxPDlzIN88US=>	MYfTRW5ITVJ?
SW626	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXZTWM2OD1\|LkK0OVQ{KM7:TR?=	M371NnNCVkeHUh?=
OCI-AML2	M2DnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TxcWlEPTB;Mz6zNVI4OiEQvF2=	NGD4PYtUSU6JRWK=
NBsusSR	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7ueVFrUUN3ME2zMlM1QTN6IN88US=>	MnLjV2FPT0WU
AN3-CA	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXJbI85UUN3ME2zMlQ1OjN6IN88US=>	MoTLV2FPT0WU
EFM-19	M2Xqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPz[lJKSzVyPUOuOFg{OzlizszN	M{joSnNCVkeHUh?=
RVH-421	NGTjdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHBTWM2OD1\|LkW2PFc4KM7:TR?=	NVKwPXcxW0GQR1XS
5637	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDVTWM2OD1\|Lk[xNVA{KM7:TR?=	NWDPVZZCW0GQR1XS
PANC-08-13	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTaTWM2OD1\|Lk[zOFczKM7:TR?=	M2PNcnNCVkeHUh?=
H9	NX[1dVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jaN2lEPTB;Mz62O\|E1PCEQvF2=	M1fWRXNCVkeHUh?=
KARPAS-299	NIPlc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTNwNkezOlEh\|ryP	NXnueVBRW0GQR1XS
TE-5	NVLPeVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrLTWM2OD1\|LkewO\|A6KM7:TR?=	NWfBUnVqW0GQR1XS
NOS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;3cIczUUN3ME2zMlc6QDN2IN88US=>	MnjWV2FPT0WU
HH	M4HH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTSNo1KSzVyPUOuPFM5PjhizszN	M1PX[HNCVkeHUh?=
769-P	NI\TeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;mVHRHUUN3ME2zMlg6PTFizszN	M2C4cXNCVkeHUh?=
CHP-212	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnFTWM2OD1\|LkmyOVQ6KM7:TR?=	MX\TRW5ITVJ?
NCI-H82	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHSe2R2UUN3ME2zMlk2QTN4IN88US=>	NHn6WlBUSU6JRWK=
Mo-T	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTRwMESzNVIh\|ryP	MlewV2FPT0WU
BB65-RCC	NEfs[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTRwMESzPVkh\|ryP	MYTTRW5ITVJ?
SW1990	M2jtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvQV5R4UUN3ME20MlA2QTB6IN88US=>	NIewSoxUSU6JRWK=
LK-2	M{LtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTRwMUGyPVMh\|ryP	MXLTRW5ITVJ?
ES5	NVX3TVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon0TWM2OD12LkGzPVg2KM7:TR?=	M4H5bnNCVkeHUh?=
JVM-3	NWO4bHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f3[2lEPTB;ND6xPFIzOiEQvF2=	NFjX[3BUSU6JRWK=
RPMI-7951	M3XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFi1bYJKSzVyPUSuNlI1OTNizszN	M13Qd3NCVkeHUh?=
Calu-6	Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYD2Vo5SUUN3ME20MlI4QDhzIN88US=>	M1faPXNCVkeHUh?=
LC-2-ad	M4f4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTRwMkm1Olgh\|ryP	M{n2dHNCVkeHUh?=
SW954	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnifIpKSzVyPUSuNlk3PiEQvF2=	MnywV2FPT0WU
H-EMC-SS	NU\sdHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILkWXpKSzVyPUSuN\|E5OzFizszN	NEH6SXBUSU6JRWK=
ES3	NXqwdVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7Y[Yd5UUN3ME20MlM2PDRzIN88US=>	MoLlV2FPT0WU
no-11	NYDkUHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTRwM{W1OVQh\|ryP	MXXTRW5ITVJ?
LAN-6	NWHqN5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzlZ25KSzVyPUSuOFUyQDlizszN	NGDGUJpUSU6JRWK=
FTC-133	M4P3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHqzbGNKSzVyPUSuOVM6PSEQvF2=	M2XjWHNCVkeHUh?=
8505C	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD1XotQUUN3ME20MlU1OjNizszN	NHLDb45USU6JRWK=
SW620	NWLYfWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTRwNUewOVch\|ryP	MVPTRW5ITVJ?
BCPAP	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6T5BrUUN3ME20MlY{PDhzIN88US=>	M1fUZ3NCVkeHUh?=
SK-LU-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[1d3JGUUN3ME20MlY3ODh7IN88US=>	NU\oPVBbW0GQR1XS
NCI-H1623	M3H5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonKTWM2OD12LkewNlI5KM7:TR?=	MVLTRW5ITVJ?
C2BBe1	NXHOV\|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXvTJpKSzVyPUSuO\|QxODhizszN	NEnVNJFUSU6JRWK=
GP5d	M1fF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRwN{izPFgh\|ryP	NVLVeGQ2W0GQR1XS
NB6	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT5NpNbUUN3ME20Mlg3OjB2IN88US=>	MUPTRW5ITVJ?
MDA-MB-157	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\VNIJKSzVyPUSuPFg4PiEQvF2=	M2f4VXNCVkeHUh?=
UMC-11	NFjmWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LkOGlEPTB;ND64PFk3PCEQvF2=	MlzSV2FPT0WU
HCC1419	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LHTmlEPTB;ND65NFA3OyEQvF2=	Mn;BV2FPT0WU
NCI-H2029	NITVVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTRwOUSxPFUh\|ryP	MoHiV2FPT0WU
LXF-289	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HjeWlEPTB;NT6wN\|cyQSEQvF2=	M122[3NCVkeHUh?=
KINGS-1	NXPyV4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7YcotKSzVyPUWuNFc4PDRizszN	NHO4[lVUSU6JRWK=
HD-MY-Z	NELGR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\RTWM2OD13LkKzPVY6KM7:TR?=	MX3TRW5ITVJ?
ESS-1	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XofWlEPTB;NT6yOVU6PyEQvF2=	MY\TRW5ITVJ?
GI-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHCT4VSUUN3ME21MlI4QTJ4IN88US=>	NWG5TYQ2W0GQR1XS
RPMI-2650	M3TQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W5R2lEPTB;NT6zOlE3KM7:TR?=	MoGwV2FPT0WU
IA-LM	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;3WGlEPTB;NT6zPVg4OSEQvF2=	MYfTRW5ITVJ?
KP-4	NYnqOFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLKdIVVUUN3ME21MlQ3OzN2IN88US=>	NFP2PG5USU6JRWK=
G-402	M37F[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHJdWpqUUN3ME21MlUyQDZ3IN88US=>	NILoZVRUSU6JRWK=
OS-RC-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mke2TWM2OD13LkWyOlA1KM7:TR?=	M1e4ZXNCVkeHUh?=
NCI-H1155	M4G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\3cWlEPTB;NT61OFk2PSEQvF2=	NHvhS4lUSU6JRWK=
OE19	NIrrfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn5[mtKSzVyPUWuOlg3OjRizszN	NGjPS2VUSU6JRWK=
U-2-OS	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHMbZI{UUN3ME21Mlg6ODF\|IN88US=>	MmDsV2FPT0WU
SCC-15	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\zTWM2OD13LkmzOlYzKM7:TR?=	NXSxT4dJW0GQR1XS
NCI-H630	NVnXbXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLWVXE3UUN3ME21Mlk6PDB2IN88US=>	NFXJSmtUSU6JRWK=
PFSK-1	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTZwMEWyOVkh\|ryP	M2CzV3NCVkeHUh?=
NCI-H1770	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\TPJZKSzVyPU[uNlA5PzRizszN	M3nnVnNCVkeHUh?=
SK-MEL-3	NUi3d3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTZwNEK5NVUh\|ryP	M3W5enNCVkeHUh?=
LB1047-RCC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6z[pRKSzVyPU[uOFc3OjVizszN	Mnf5V2FPT0WU
NCI-H446	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV23WoJ6UUN3ME22MlYzQTJ3IN88US=>	M3f2S3NCVkeHUh?=
SW780	NGXXPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWX1UWFkUUN3ME22MlcxOTh3IN88US=>	MnrIV2FPT0WU
NEC8	NWjsR4ptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDMcm5KSzVyPU[uO\|Y3OyEQvF2=	M{H1PXNCVkeHUh?=
NOMO-1	NFnaOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHGe5lKSzVyPU[uO\|gyOTFizszN	MnzPV2FPT0WU
COLO-668	NU\oSndGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoGzTWM2OD14Lki0N\|g4KM7:TR?=	Mn\tV2FPT0WU
MC116	NEDQeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTZwOUO4PVch\|ryP	NVXNemR[W0GQR1XS
HCC1937	Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorFTWM2OD14Lkm5NlUyKM7:TR?=	MVHTRW5ITVJ?
NCI-N87	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD2dmlGUUN3ME23MlE6Ojl\|IN88US=>	MVLTRW5ITVJ?
COLO-320-HSR	NX\hd3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TZUmlEPTB;Nz6yNlc{QCEQvF2=	MorpV2FPT0WU
HCC1806	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\vO2pUUUN3ME23MlI3ODR2IN88US=>	NYPTUlF2W0GQR1XS
OVCAR-3	NH;zdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7MeY9KSzVyPUeuN\|MxOzhizszN	MWnTRW5ITVJ?
NUGC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXwd5hDUUN3ME23MlM6Pjl2IN88US=>	NYHHd4ZMW0GQR1XS
SW1783	NV\ZSIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF30eGdKSzVyPUeuOFMyPzVizszN	MYjTRW5ITVJ?
GCT	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTdwNU[5NFYh\|ryP	MlH4V2FPT0WU
NCI-H2126	M4e2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD4dpdKSzVyPUeuO\|M3OjVizszN	MY\TRW5ITVJ?
MEL-HO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPRTWM2OD15Lke3NFU1KM7:TR?=	NWrrUVdsW0GQR1XS
CAPAN-1	M4PwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTdwN{ezOVch\|ryP	NG\HeZNUSU6JRWK=
SW756	NFPjNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTzTWM2OD15Lke4N\|M{KM7:TR?=	NHy5T\|NUSU6JRWK=
SKG-IIIa	NIO5SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnK3TWM2OD15LkixPFkzKM7:TR?=	Mm\rV2FPT0WU
HCE-T	NGO5cVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzc\|FoUUN3ME23Mlg4Pzh\|IN88US=>	MWHTRW5ITVJ?
Ca-Ski	NVTMT4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDFdWNKSzVyPUeuPVk{QDNizszN	Ml32V2FPT0WU
COLO-684	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRThwMEG4NVgh\|ryP	MXzTRW5ITVJ?
KYSE-70	NYXv[ph2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFeyUWxKSzVyPUiuNFc4OjlizszN	M{m2WHNCVkeHUh?=
TI-73	NXflPIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjGenF2UUN3ME24MlI2QDVzIN88US=>	MlH0V2FPT0WU
BT-20	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLKbHNKSzVyPUiuNlYxPTJizszN	MWPTRW5ITVJ?
MHH-ES-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjQc4pKSzVyPUiuOVE5OzRizszN	MVjTRW5ITVJ?
TE-12	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq4TWM2OD16LkW5PVMyKM7:TR?=	MUDTRW5ITVJ?
YH-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33JRmlEPTB;OD62NVAxQCEQvF2=	M2DhbnNCVkeHUh?=
SF126	NEHEWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHl[4FKSzVyPUiuPFM5PjVizszN	NUPhS5h1W0GQR1XS
J82	M37yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRThwOUCwN\|gh\|ryP	M{fNdXNCVkeHUh?=
RCC10RGB	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnvTWM2OD16Lkm5OVYyKM7:TR?=	NUjwT4FPW0GQR1XS
SK-UT-1	NHqxdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTlwMES5OFUh\|ryP	NXK3VWJPW0GQR1XS
LB2241-RCC	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTlwMUmxN\|ch\|ryP	M323fnNCVkeHUh?=
LB996-RCC	NHXUUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHkU2dCUUN3ME25MlE6QDlizszN	NUjSNo1GW0GQR1XS
EPLC-272H	NWn6eGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjLOmZKSzVyPUmuN\|c3PTdizszN	NX3tRYkxW0GQR1XS
CTV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTlwNU[1N\|Ih\|ryP	NX7vcJM1W0GQR1XS
HSC-2	M1n2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7JR\|RoUUN3ME25MlU4PTVizszN	MoXpV2FPT0WU
SK-MEL-28	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjlSJJKSzVyPUmuOlE5QTNizszN	NHr1S5hUSU6JRWK=
MMAC-SF	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTlwNki3OUDPxE1?	MWrTRW5ITVJ?
CP50-MEL-B	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTlwN{W3PFIh\|ryP	MnzQV2FPT0WU
HT-1080	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDhZm5KSzVyPUmuO\|c4OzlizszN	NW\kZY9SW0GQR1XS
HEC-1	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHhO2pKSzVyPUGwMlM{PTJizszN	NI\6SItUSU6JRWK=
AGS	NUnzd2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFyLkO3OEDPxE1?	NFrBVZdUSU6JRWK=
GAMG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj3WZBmUUN3ME2xNE42OTZ{IN88US=>	M4O4NnNCVkeHUh?=
SW48	NHj3WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;BemFKSzVyPUGwMlUyQDlizszN	MXTTRW5ITVJ?
U031	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTFyLkW5NFgh\|ryP	MmrXV2FPT0WU
OVCAR-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2W2c2lEPTB;MUCuOlQzQSEQvF2=	NVrxblBYW0GQR1XS
SF295	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjKfpN6UUN3ME2xNE43PzB2IN88US=>	NGDtSIxUSU6JRWK=
BHT-101	NVziXmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\wXnJKSzVyPUGwMlcyPzdizszN	MVXTRW5ITVJ?
VMRC-RCZ	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFzLkOyNFEh\|ryP	MWrTRW5ITVJ?
ACHN	NXjlW\|NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTFzLkSyNVEh\|ryP	MmrrV2FPT0WU
NCI-H526	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnZZ3RKSzVyPUGxMlUxPDNizszN	NU\yZ412W0GQR1XS
MN-60	NXz3dWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2KyVGlEPTB;MUGuOVM6KM7:TR?=	MVrTRW5ITVJ?
NCI-H2291	M37sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr0VJZvUUN3ME2xNU42PDZ4IN88US=>	MYfTRW5ITVJ?
SCC-25	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH6wUW9KSzVyPUGxMlc2PTZizszN	Mm\4V2FPT0WU
SK-MEL-2	NGLF[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33YU2lEPTB;MUGuO\|Y{PyEQvF2=	MWHTRW5ITVJ?
SN12C	NHLr[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTFzLkmzOVUh\|ryP	Mly2V2FPT0WU
NCI-H69	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTF{LkSyN\|Qh\|ryP	M2HmSHNCVkeHUh?=
ME-180	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjS[YVpUUN3ME2xNk44ODV2IN88US=>	MmrCV2FPT0WU
MC-IXC	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF{Lke1NVgh\|ryP	NH20V4VUSU6JRWK=
NCI-H2347	M3W4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTPdGFSUUN3ME2xNk44PjF2IN88US=>	MXnTRW5ITVJ?
M059J	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HnemlEPTB;MUKuO\|czPyEQvF2=	M1rFfXNCVkeHUh?=
A2058	NUPY[lE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4L6VmlEPTB;MUKuPFY5OSEQvF2=	M3TlUHNCVkeHUh?=
VA-ES-BJ	NUXVfoJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jnT2lEPTB;MUKuPFc5PSEQvF2=	NXHTcIJpW0GQR1XS
Ca9-22	NHH4V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X4eGlEPTB;MUKuPVQ2OSEQvF2=	M2C5c3NCVkeHUh?=
KNS-42	M1fHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLsPHZKSzVyPUGyMlk6QDRizszN	MY\TRW5ITVJ?
LoVo	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{W3c2lEPTB;MUOuNlMyOyEQvF2=	NGK4O2VUSU6JRWK=
AM-38	NHHmeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXhW4hKSzVyPUGzMlI2PjZizszN	NFLUb4RUSU6JRWK=
NB5	M376Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD2RlI6UUN3ME2xN{4{PzV{IN88US=>	NFPNO4tUSU6JRWK=
L-363	NUPzfnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrrbYtrUUN3ME2xN{41ODN\|IN88US=>	Mnr6V2FPT0WU
SK-MEL-30	NV\zc25FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF2LkC2OFUh\|ryP	MojUV2FPT0WU
NCI-H1563	M1W5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF2Lk[wN\|kh\|ryP	NVrLWlBMW0GQR1XS
NCI-H2228	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\qOWNKSzVyPUG0MlYxPzdizszN	M{nt[HNCVkeHUh?=
MFM-223	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV6wcJNzUUN3ME2xOU4yQDF\|IN88US=>	NHjEXYxUSU6JRWK=
LB831-BLC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTF3LkK3Olch\|ryP	M4\KNnNCVkeHUh?=
SW872	NHf2fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH3TWM2OD1zNT6zNFg3KM7:TR?=	NUHDVXYzW0GQR1XS
NCI-H522	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPLPGhKSzVyPUG1MlM{ODZizszN	M3HYUHNCVkeHUh?=
EW-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHDZWRKSzVyPUG1MlU1PjJizszN	NEG1eJZUSU6JRWK=
HN	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fRT2lEPTB;MUWuOVk1OiEQvF2=	M4\VZXNCVkeHUh?=
SW837	M1LMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\iflBLUUN3ME2xOU44QDR5IN88US=>	MUDTRW5ITVJ?
SCC-9	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTYWW9KSzVyPUG1MlgyOTRizszN	NVfZ[GRUW0GQR1XS
MKN7	NITVdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3jPY1KSzVyPUG1Mlk4OzJizszN	NIDMNo9USU6JRWK=
KYSE-410	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF4LkW5NUDPxE1?	NV;JcVVSW0GQR1XS
SK-N-DZ	NX;0SYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFK4dFNKSzVyPUG2MlYyOTZizszN	MUjTRW5ITVJ?
COR-L105	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXaXVFoUUN3ME2xOk43PTJ6IN88US=>	NHj5Z5RUSU6JRWK=
LB2518-MEL	M1PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvUfm9KSzVyPUG2Mlg{QDlizszN	M2rIfXNCVkeHUh?=
OVCAR-4	NVr3NoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF4Lki4OlIh\|ryP	NH3JWWhUSU6JRWK=
TK10	NV3KfoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1iwSWlEPTB;MU[uPVQ4OyEQvF2=	M{PKU3NCVkeHUh?=
KNS-62	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTF4Lkm3O\|ch\|ryP	M37LOnNCVkeHUh?=
RPMI-8866	M4DxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTF5LkG3N\|Ih\|ryP	MXfTRW5ITVJ?
HuP-T4	NFGyWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF5LkK0PVUh\|ryP	NFv5[\|NUSU6JRWK=
CGTH-W-1	NYrTTlc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3FdGhuUUN3ME2xO{42OjF7IN88US=>	NHTMTlNUSU6JRWK=
T-24	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{L0TGlEPTB;MUeuOVM1PyEQvF2=	NYnidZR4W0GQR1XS
HT-3	M3TQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTF5LkW5NVQh\|ryP	NVP2TY9yW0GQR1XS
KS-1	M{fKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTF5Lk[3N{DPxE1?	MXrTRW5ITVJ?
NCI-H1792	NVzr[I1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPReoxnUUN3ME2xO{44QThizszN	NETONpVUSU6JRWK=
ABC-1	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkG4TWM2OD1zNz64NVQyKM7:TR?=	NYflPXA2W0GQR1XS
BPH-1	NXuySIxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTF6LkG2PFUh\|ryP	NXrQRmRxW0GQR1XS
A431	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnsdY1KSzVyPUG4MlQyOjdizszN	NIHiXFdUSU6JRWK=
T98G	NUfwSIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;mbVdpUUN3ME2xPE42OTV5IN88US=>	M3KyT3NCVkeHUh?=
BHY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET3VWFKSzVyPUG4Mlg3QSEQvF2=	NF24[YFUSU6JRWK=
Capan-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTF6LkmwO\|gh\|ryP	MnLQV2FPT0WU
MDA-MB-175-VII	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHX0Tm1KSzVyPUG4MlkzODlizszN	M{nScnNCVkeHUh?=
CAL-27	NYfTPXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M161SGlEPTB;MUmuNFQ5PyEQvF2=	MYnTRW5ITVJ?
AsPC-1	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF7Lki2OVch\|ryP	MofrV2FPT0WU
KU812	NXL2fJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTF7Lkm1O\|Mh\|ryP	MXrTRW5ITVJ?
NCI-H441	M1;RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzsdnFKSzVyPUKwMlAxOSEQvF2=	NEPEPIFUSU6JRWK=
Mewo	NHP5c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJyLkGyPFgh\|ryP	MlXmV2FPT0WU
SK-MEL-24	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfJTWM2OD1{MD6xOFc4KM7:TR?=	MmfmV2FPT0WU
NCI-H727	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TJeWlEPTB;MkCuNlcxPCEQvF2=	NWDhdYJbW0GQR1XS
EKVX	M4P3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\yeHRKSzVyPUKwMlYxPiEQvF2=	NVrHeVNlW0GQR1XS
RT-112	NVryOIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPUTWM2OD1{MD62NVIzKM7:TR?=	NHfZOnRUSU6JRWK=
CAMA-1	NVL6VpoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfqR49KSzVyPUKwMlk5ODNizszN	M322T3NCVkeHUh?=
SW900	NHfFcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTlSZlKUUN3ME2yNU4xOTR7IN88US=>	M3XWe3NCVkeHUh?=
NCI-H23	NFjhWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJzLkGyO\|ch\|ryP	MXPTRW5ITVJ?
SK-PN-DW	NYHVTppYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJzLkG2OFkh\|ryP	NG\M[2lUSU6JRWK=
BB30-HNC	M3nrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{C0NGlEPTB;MkGuNlc1PSEQvF2=	M2D0XnNCVkeHUh?=
VM-CUB-1	NEnTWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\CeGlEPTB;MkGuN\|U{PiEQvF2=	MWXTRW5ITVJ?
IST-MEL1	M3\XVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPqfYF[UUN3ME2yNU4{Pjl{IN88US=>	M1fnZXNCVkeHUh?=
CTB-1	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1naTGlEPTB;MkGuOFc2PSEQvF2=	NWLU[41VW0GQR1XS
LCLC-103H	NX;QU3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLG[HMxUUN3ME2yNk4yPTh{IN88US=>	M{\Be3NCVkeHUh?=
PANC-03-27	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTJ{LkWxOlkh\|ryP	NUnaXWpXW0GQR1XS
HTC-C3	M4nCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2niXWlEPTB;MkKuOVU2PSEQvF2=	NIjtSY5USU6JRWK=
TE-8	NIe5dYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXHTWM2OD1{Mz6yOVY2KM7:TR?=	NWPr[mF3W0GQR1XS
NCI-H292	NFT4[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjsOJpNUUN3ME2yOU4{PTN4IN88US=>	MlLXV2FPT0WU
COLO-680N	NIra[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvRWmlKSzVyPUK1MlY{OjlizszN	NYi2TmtMW0GQR1XS
KYSE-520	NXTwUpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHPTWM2OD1{NT62OFQh\|ryP	MVXTRW5ITVJ?
NB10	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFroTnZKSzVyPUK2MlMyOTdizszN	MX;TRW5ITVJ?
NCI-H661	NH6zNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnyW2lKSzVyPUK2MlQ4OTNizszN	MlfOV2FPT0WU
GMS-10	NXrIfWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJ4Lki2N\|gh\|ryP	MXXTRW5ITVJ?
NCI-H2122	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O5SWlEPTB;Mk[uPVk6QCEQvF2=	NG\uNGFUSU6JRWK=
OVCAR-8	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PxOWlEPTB;MkeuNFY{QCEQvF2=	NXzNRXVxW0GQR1XS
DJM-1	NIDEdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLN[2pKSzVyPUK3MlE1PTRizszN	MXLTRW5ITVJ?
UACC-893	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLifo9KSzVyPUK3Mlk5PzhizszN	NFPxdIVUSU6JRWK=
C8166	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJ6Lk[5N\|gh\|ryP	MVfTRW5ITVJ?
NCI-H1693	NVfUbHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfwUXlKSzVyPUK4MlY6PzVizszN	MX3TRW5ITVJ?
TYK-nu	NGnTS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkK5TWM2OD1\|MD6wN\|Q2KM7:TR?=	NFzlXWxUSU6JRWK=
SW1710	M33pTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfPTYRnUUN3ME2zNE4yOjZizszN	MXrTRW5ITVJ?
A375	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;uTWM2OD1\|MD6zNlQ{KM7:TR?=	NVzrcJhxW0GQR1XS
HMV-II	NFi0N3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTNzLkO1PVIh\|ryP	M{j1WnNCVkeHUh?=
NCI-H2087	NFG5fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fMcmlEPTB;M{GuOlM2OiEQvF2=	NX\lTmJ4W0GQR1XS
CAL-54	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTNzLkeyOFEh\|ryP	M2fZSXNCVkeHUh?=
HCC70	NVi3SlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTYNWF2UUN3ME2zNk4yOzh5IN88US=>	MkPBV2FPT0WU
ES1	NHTFWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K0UGlEPTB;M{KuN\|A3OiEQvF2=	M3naUXNCVkeHUh?=
NCI-H1355	M33memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPETWM2OD1\|Mz6yNFQh\|ryP	NW\TcYI4W0GQR1XS
CFPAC-1	NXLVeWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\WOGlEPTB;M{OuNlM{OiEQvF2=	NWDYXIlQW0GQR1XS
MKN28	M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3tTWM2OD1\|Mz6zPFA6KM7:TR?=	MkDyV2FPT0WU
HDLM-2	M2Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTN\|Lk[5N\|Eh\|ryP	MoTvV2FPT0WU
PANC-10-05	M4jkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XUVGlEPTB;M{SuNVAyPCEQvF2=	NWLqOHBLW0GQR1XS
SAS	M3Lremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUCxOlJLUUN3ME2zOE41PTZ3IN88US=>	NX\iTWpxW0GQR1XS
HCC1395	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTN2LkexPFYh\|ryP	NITL[XpUSU6JRWK=
8305C	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrLOmFKSzVyPUO1Mlg1OTVizszN	NVrpd4N{W0GQR1XS
KM12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjoRoY1UUN3ME2zOk44PTR5IN88US=>	NGXJUYVUSU6JRWK=
SW1116	NYfjW2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGntVGVKSzVyPUO3MlU6QTJizszN	MV;TRW5ITVJ?
SK-MEL-1	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PqZWlEPTB;M{iuN\|M5QSEQvF2=	MXLTRW5ITVJ?
HCC2218	M3;iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES0O4xKSzVyPUO4MlY2OTlizszN	NV\WfnBoW0GQR1XS
T84	NE\ielBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDOT496UUN3ME2zPE44PDB7IN88US=>	NHzXbIhUSU6JRWK=
ETK-1	NGKwOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K4R2lEPTB;M{muNFIzKM7:TR?=	M2eze3NCVkeHUh?=
COLO-800	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq1TWM2OD1\|OT6zPFY5KM7:TR?=	MWPTRW5ITVJ?
CAL-12T	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW3TWM2OD1\|OT61NlgyKM7:TR?=	NInaVXdUSU6JRWK=
ACN	NEXyU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInsNWNKSzVyPUSwMlQ6OTFizszN	NUjDbnFlW0GQR1XS
SJSA-1	NX7UNZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn65TWM2OD12MT6xOVk3KM7:TR?=	MnjpV2FPT0WU
PSN1	NEjBNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHtcohKSzVyPUSxMlE4PDlizszN	M{nh[nNCVkeHUh?=
D-566MG	NF3uOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fRRmlEPTB;NEGuNlA5PiEQvF2=	NXLKS5RZW0GQR1XS
EGI-1	NFLjO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTteFRKSzVyPUSyMlQzQCEQvF2=	MUHTRW5ITVJ?
A204	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHiyZmdKSzVyPUSyMlY{QDhizszN	M4HxfXNCVkeHUh?=
Saos-2	M4Luemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\CNI1KSzVyPUSyMlg{PjlizszN	NWDqeoJTW0GQR1XS
SNU-C2B	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2H1PGlEPTB;NEOuOlg4QCEQvF2=	MWLTRW5ITVJ?
HLE	NEfSXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTVTWM2OD12ND6wPFU3KM7:TR?=	NEnk[4RUSU6JRWK=
SW1463	NUjndZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGraOZRKSzVyPUS0Mlk6PzFizszN	MWHTRW5ITVJ?
DSH1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrROJlYUUN3ME20OU4xODN\|IN88US=>	MX3TRW5ITVJ?
MCF7	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjscZNKSzVyPUS1MlUxPTFizszN	M3HCfnNCVkeHUh?=
K5	NXv6emtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTR3Lkm0NFUh\|ryP	NV7GNm8yW0GQR1XS
NCI-H358	M4fRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2xTWM2OD12Nz6yNVUh\|ryP	NXv0R3pZW0GQR1XS
NCI-H2030	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrOcG9KSzVyPUS3MlI{PzRizszN	MXPTRW5ITVJ?
SW948	M2HGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfKS4NKSzVyPUS3MlQ3PCEQvF2=	MmTOV2FPT0WU
BALL-1	M2HqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTwRXA1UUN3ME20O{43OTZ6IN88US=>	MoPRV2FPT0WU
TE-9	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{n5VWlEPTB;NEeuPVU5OSEQvF2=	NFLHRoFUSU6JRWK=
SK-N-FI	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnRNldKSzVyPUS4MlA{PThizszN	MnK3V2FPT0WU
KALS-1	M4XNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHaU29FUUN3ME20PE4yOjh7IN88US=>	MW\TRW5ITVJ?
HO-1-N-1	NITkdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTR6Lke0OFUh\|ryP	M2\RXnNCVkeHUh?=
NCI-H2452	NUfIe4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTR7LkGxOVIh\|ryP	MYPTRW5ITVJ?
OC-314	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTR7Lk[4N\|Qh\|ryP	NYK2[pBQW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Active not recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Lung Carcinoma\|Advanced Malignant Solid Neoplasm\|Advanced Pancreatic Carcinoma\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)